Product Description
to measure impedance during inpatient treatment (Sourced from: https://clinicaltrials.gov/ct2/history/NCT01509495?V_3=View)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Medtronic
Company Location: DUBLIN L2 2
Company CEO: Geoffrey S. Martha
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Heart Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SIM-HF | P1 |
Terminated |
Heart Failure |
2014-05-01 |